TECH · US market

Bio-Techne Corp

Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.

Market cap US$11.35bnFinancials dated 30 June 2026Price dated 1 October 2026

Core valuation

Trailing P/E62.43×

Latest-quarter run-rate P/E51.95×

Trailing P/S9.34×

Latest-quarter run-rate P/S8.84×

Calculation inputs

Trailing earnings: US$181.86m
Latest-quarter run-rate earnings: US$218.56m
Latest fiscal-year earnings: US$181.84m
Trailing revenue: US$1.22bn
Latest-quarter run-rate revenue: US$1.28bn
Latest fiscal-year revenue: US$1.22bn

Featured ETF and mutual-fund exposure

These public funds report this company in their latest disclosed holdings.

DFMGX · DF Dent Midcap Growth Fund Institutional Shares3.98% weight · Holdings dated 30 June 2026
MSCFX · Mairs & Power Small Cap Fund3.93% weight · Holdings dated 30 June 2026
FBT · First Trust NYSE Arca Biotechnology Index Fund3.43% weight · Holdings dated 30 June 2026
GNOM · Global X Genomics & Biotechnology ETF3.31% weight · Holdings dated 31 May 2026
BCSSX · Brown Capital Management Small Company Fund Institutional Shares2.88% weight · Holdings dated 30 June 2026
FSMEX · Fidelity Select Medical Technology and Devices Portfolio2.85% weight · Holdings dated 31 May 2026
IBBQ · Invesco Nasdaq Biotechnology ETF2.73% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
PBE · Invesco Biotechnology & Genome ETF2.73% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
WVAIX · Weitz Large Cap Equity Fund - Institutional Class2.26% weight · Holdings dated 30 June 2026
FMED · Fidelity Disruptive Medicine ETF2.24% weight · Holdings dated 31 May 2026

Sources and limitations

Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.

Open financial source

Financials as of 30 June 2026. Informational research, not investment advice.